RxDoctor Payments Data

Maria Guzman, MD

General Practice · Kissimmee, FLNPI 1750564969

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 54 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$273
  • Bayer$255
  • AstraZeneca$221
  • Ensodata, Inc.$154
  • Exact Sciences$80
  • Johnson & Johnson$37
  • plus $170 from 9 others

What the payments were for

  • Food & beverage$1,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,190 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$9,390
Medicare patients
26
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$129,559
JardianceEmpagliflozin60$82,438
EliquisApixaban55$68,838
FarxigaDapagliflozin Propanediol46$59,994
TrulicityDulaglutide39$50,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$47,883
JanumetSitagliptin Phos/Metformin Hcl24$34,415
RybelsusSemaglutide16$28,411
KerendiaFinerenone13$23,514
JanuviaSitagliptin Phosphate16$21,918
VascepaIcosapent Ethyl32$21,166
MyrbetriqMirabegron16$19,387
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,876
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$9,148
Novolog FlexpenInsulin Aspart17$5,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$273$157,969147 claims
Boehringer IngelheimJardiance$16$82,43860 claims
PfizerEliquis$21$68,83855 claims
AstraZenecaFarxiga, Symbicort$221$63,36160 claims
Lilly USA, LLCTrulicity$22$50,13139 claims
GSKTrelegy Ellipta$22$47,88348 claims
BayerKerendia$255$23,51413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.

Other general practice in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →